Aerovance raises cash for inhaled Aerovant trials
This article was originally published in Scrip
Executive Summary
Aerovance has secured $38 million to support a Phase IIb clinical trial and future studies of its inhaled Aerovant in patients with uncontrolled asthma. The firm has already closed $20 million of the equity financing and can call the remaining $18 million after six months.